| Ms Kelsey Marie Rosenquist, SLP | |
|
4921 Parkview Pl, Dept Otolaryngology, Ste 11a, Saint Louis, MO 63110-1032 | |
| (314) 362-7509 | |
| (314) 362-7522 |
| Full Name | Ms Kelsey Marie Rosenquist |
|---|---|
| Gender | Female |
| Speciality | Qualified Speech Language Pathologist |
| Experience | 10 Years |
| Location | 4921 Parkview Pl, Saint Louis, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467843334 | NPI | - | NPPES |
| 460020190 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 2015015953 (Missouri) | Secondary |
| 235Z00000X | Speech-language Pathologist | 2015015953 (Missouri) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Washington University | 9830008770 | 2506 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera as a potential therapy for Lipoprotein Lipase Deficiency.
The U.S. Food and Drug Administration today approved Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and older.
Caprion - HistoGeneX announced today that the company is launching a molecular PCR testing service for identifying patients with COVID-19.
A joint University of Adelaide-Shanghai Jiao Tong University study has provided the first broad picture of the evolution and possible functions in the plant of pollen allergens.
› Verified 1 days ago
| Entity Name | Washington University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356381842 PECOS PAC ID: 9830008770 Enrollment ID: O20041013000030 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera as a potential therapy for Lipoprotein Lipase Deficiency.
The U.S. Food and Drug Administration today approved Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and older.
Caprion - HistoGeneX announced today that the company is launching a molecular PCR testing service for identifying patients with COVID-19.
A joint University of Adelaide-Shanghai Jiao Tong University study has provided the first broad picture of the evolution and possible functions in the plant of pollen allergens.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Kelsey Marie Rosenquist, SLP Po Box 60352, Saint Louis, MO 63160-0352 Ph: (314) 362-7509 | Ms Kelsey Marie Rosenquist, SLP 4921 Parkview Pl, Dept Otolaryngology, Ste 11a, Saint Louis, MO 63110-1032 Ph: (314) 362-7509 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera as a potential therapy for Lipoprotein Lipase Deficiency.
The U.S. Food and Drug Administration today approved Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and older.
Caprion - HistoGeneX announced today that the company is launching a molecular PCR testing service for identifying patients with COVID-19.
A joint University of Adelaide-Shanghai Jiao Tong University study has provided the first broad picture of the evolution and possible functions in the plant of pollen allergens.
› Verified 1 days ago